Patent intelligence · US
US 11564926
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
Patent details — US 11564926
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2023
- Expiration
- Jan 26, 2043
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K31/50, A61K31/53, A61P
Quick answer
US 11564926 (Methods of synthesizing thyroid hormone analogs and polymorphs thereof) is held by Madrigal Pharmaceuticals, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/50, A61K31/53, A61P, A61P5/14, A61P9/00
More from Madrigal Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377104
Methods for treating a fatty liver disease
granted -
US 11986481
Method of synthesizing thyroid hormone analogs and polymorphs thereof
granted -
US 11806353
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted -
US 11491145
Combination therapies comprising targeted therapeutics
granted -
US 11377447
Targeted therapeutics
granted -
US 11090308
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted -
US 10894050
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
granted
Frequently asked questions
What is US patent 11564926?
US 11564926 (Methods of synthesizing thyroid hormone analogs and polymorphs thereof) is held by Madrigal Pharmaceuticals, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11564926?
Madrigal Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 11564926 expire?
Our index shows an expiration date of Jan 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.